EMA approves coformulated atazanavir/cobicistat
EMA press release
On 21 May 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended approval in the EU for the combined formulation of atazanavir/cobicistat (300 mg/150 mg) film coated tablets.
The indication is for use with other antiretrovirals to treat HIV-1 in people without mutations associated with drug resistance to atazanavir.
This combines the protease inhibitor atazanavir with the PK booster cobicistat in a single pill. The brand name is Evotaz and it is manufacted by Bristol-Myers Squibb.
For full details see the summary of product characteristics (SmPC).
Committee for Medicinal Products for Human Use (CHMP). Evotaz Summary of opinion (initial authorisation). EMA/CHMP/277547/2015. (21 May 2015).